<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01268761</url>
  </required_header>
  <id_info>
    <org_study_id>0810-C-052-JG</org_study_id>
    <nct_id>NCT01268761</nct_id>
  </id_info>
  <brief_title>GnRH Antagonist for Treatment of Early Ovarian Hyperstimulation Syndrome</brief_title>
  <official_title>Usefulness of GnRH Antagonist Administration in the Treatment of Early Ovarian Hyperstimulation Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Instituto Valenciano de Infertilidad, IVI VALENCIA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Instituto Valenciano de Infertilidad, IVI VALENCIA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to analyze the effectiveness of GnRh antagonist in the treatment of
      early ovarian hyperstimulation syndrome.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Ovarian hyperstimulation syndrome (OHSS) is a serious complication of ovarian stimulation
      protocols. Gonadotrophin-releasing hormone (GnRH) antagonist administration in the luteal
      phase was recently proposed as a new approach for the management of patients with established
      severe OHSS We analyze the response of egg donors with moderate- severe early ovarian
      hyperstimulation syndrome after a GnRH antagonist stimulation protocol to the administration
      of a daily doses of GnRH antagonist (Cetrorelix 0.25) during 7 days after the second day of
      oocyte retrieval compared with placebo (saline solution).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2012</start_date>
  <completion_date type="Actual">July 2013</completion_date>
  <primary_completion_date type="Actual">July 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Ultrasound</measure>
    <time_frame>one week</time_frame>
    <description>Ultrasound measurements: ascitis and ovarian size</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blood measurements</measure>
    <time_frame>one week</time_frame>
    <description>Blood measurements: hyperstimulation biomarkers, liver and kidney function and hormonal profile.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Ovarian Hyperstimulation Syndrome</condition>
  <condition>Effects of Gonadotropin</condition>
  <condition>Oocyte Maturation</condition>
  <arm_group>
    <arm_group_label>GnRH antagonist</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>• GnRH antagonist (Cetrorelix 0.25)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo (saline solution)</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>• Placebo (saline solution)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GnRH antagonist (Cetrorelix)</intervention_name>
    <description>•GnRH antagonist (Cetrorelix 0.25) during 7 days beginning administration the second day of oocyte retrieval</description>
    <arm_group_label>GnRH antagonist</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo (saline solution)</intervention_name>
    <description>• Placebo (saline solution) 1 ampoule every 24 hours during 7 days beginning administration the second day of oocyte retrieval</description>
    <arm_group_label>Placebo (saline solution)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Egg donors

          -  Volunteers.

          -  18-35 years old

          -  Healthy

          -  BMI &lt; 30

          -  OHHS after oocyte retrieval defined as ascitis &gt; 9 cm2 associate to abdominal pain,
             sickness, abdominal distention,or haematocrit (Ht) &gt;45% an white blood cell count
             &gt;15,000/mm3 or creatine &gt; 1.2 mg/dl or transaminases &gt; 40 IU/liter

        Exclusion Criteria:

          -  BMI &gt; 30

          -  Allergy to GnRH antagonist
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Juan Giles, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>IVI Valencia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>IVI Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46015</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>September 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 23, 2010</study_first_submitted>
  <study_first_submitted_qc>December 30, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2010</study_first_posted>
  <last_update_submitted>September 18, 2013</last_update_submitted>
  <last_update_submitted_qc>September 18, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 19, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Instituto Valenciano de Infertilidad, IVI VALENCIA</investigator_affiliation>
    <investigator_full_name>Juan Giles</investigator_full_name>
    <investigator_title>Principal Investigator; Gynecologist IVI Valencia</investigator_title>
  </responsible_party>
  <keyword>Ovarian hyperstimulation syndrome (OHSS)</keyword>
  <keyword>GnRH antagonist</keyword>
  <keyword>Ascitis.</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Ovarian Hyperstimulation Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pharmaceutical Solutions</mesh_term>
    <mesh_term>Cetrorelix</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

